The increased risk of falls associated with the intake of SGLT2 inhibitors alone, and in combination with GLP-1RAs, suggests that caution should be exercised when these drugs are administered to sarcopenia-affected persons with type 2 diabetes. Here, SLC5A2 is linked to sarcopenia.